Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702

Clicks: 14
ID: 329963
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #342 of 407 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 407 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Postoperative circulating tumor DNA (ctDNA) is a highly prognostic marker of residual disease among patients with stage III colon cancer, and physical activity has been associated with improved survival after curative resection. Whether physical activity predicts outcomes according to postoperative ctDNA status remains unknown. METHODS: We conducted a post hoc analysis of CALGB/SWOG 80702, a phase III study evaluating adjuvant celecoxib vs. placebo and 3 vs. 6 months of chemotherapy. Total physical activity volume was assessed using validated and quantified in metabolic equivalent task hours per week (MET-h/week). ctDNA status was determined using a clinically validated, tumor-informed assay (SignateraTM, Natera, Inc.). RESULTS: Among 763 patients (median follow-up 6.0 years), 32.3% were inactive (<3.0 MET-h/week), 24.4% were highly active (≥18.0), and 17.8% were ctDNA-positive. Among patients who were ctDNA-negative, moderate (adjusted hazard ratio [HR] 0.58, 95% confidence interval [CI] 0.37-0.91) and high physical activity (HR 0.49, 95% CI 0.27-0.86) were associated with improved disease-free survival (DFS) compared to inactivity, with similar trends in overall survival (OS). Physical activity was not associated with DFS/OS in the ctDNA-positive subcohort (P > 0.05 for all), though interactions were not statistically significant. Among patients who were physically active (≥9.0 MET-h/week) and received adjuvant celecoxib, improved DFS was observed in both ctDNA-negative (HR 0.41, 95% CI 0.22-0.77) and ctDNA-positive (Ref: inactive, placebo; HR 0.29, 95% CI 0.15-0.57) subgroups. CONCLUSIONS: Greater physical activity was associated with improved DFS among patients who were ctDNA-negative. Physical activity and adjuvant celecoxib was associated with favorable survival outcomes regardless of ctDNA status.
Reference Key
openalex_W7214368920 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors George Q. Zhang, Chao Ma, Victor Boya Yang, Qian Shi, Jonathan A Nowak, Levi Pederson, Tyler Twombly, Juha P. Väyrynen, Melissa Zhao, Yasutoshi Takashima, Ardaman Shergill, Pankaj Kumar, Félix Couture, J Philip Kuebler, Smitha Krishnamurthi, Benjamin Tan, Eileen M. O´Reilly, Shuji Ogino, Joel E. Goldberg, Justin C. Brown, Adham Jurdi, Anthony F Shields, Jeffrey A Meyerhardt
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag342
URL
https://doi.org/10.1093/jnci/djag342
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.